Articles related to TYPE 1 DIABETES
Saving Sight in Your Patients with Diabetes: What You Might Be Missing
Participants should be better able to discuss anti-VEGF therapy outcomes in patients with moderate-severe and severe nonproliferative diabetic retinopathy after taking part in this educational activity with Drs. Susan Bressler, Mark Dunbar, and Ruth Weinstock, and understand the importance of prompt referral and early diagnosis to reduce or even prevent the vision-threatening complications of diabetes.
Endocrinology, Diabetes, Metabolism January 26th 2023
Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update
A layered approach to care is described with lifestyle interventions being a key feature of the updated recommendations. The recommendations now include therapies proven to improve cardiovascular and kidney outcomes in patients with diabetes and CKD.
Cardiology January 19th 2023
Competitor Poised to Take on Obesity Treatment Giant Wegovy in 2023
Fast-tracked tirzepatide is looking to join the diabetes-turned-obesity drug market. Additional options in the class could be a boon to patients, given the persisting semiglutide shortage.
Endocrinology, Diabetes, Metabolism January 10th 2023
ADA Updates Diabetes Standards of Care for 2023
The updated ADA standards have several significant changes. These include: A revised definition of HTN to match that of the ACC and AHA New recommendations for statin use Changes to recommendations around CKD treatment Revised weight loss goals Use of diabetes technology And much more
Endocrinology, Diabetes, Metabolism January 5th 2023
FDA Approves First Drug to Delay Onset of Type 1 Diabetes
In comparison to 72% of patients who received placebo, 45% of those who received teplizumab-mzwv (Tzield, Provention Bio) over the course of a median follow-up of 51 months were found to have stage 3 type 1 diabetes. Teplizumab-mzwv appeared to delay the onset of type 1 diabetes by about two years, as the median time from randomization to diagnosis of stage 3 diabetes was 50 months in the teplizumab-mzwv group and 25 months in the placebo group.
Clinical Pharmacology November 29th 2022
GLP-1 Receptor Agonists Associated with Thyroid Cancer
Looking at 2,500 case patients mapped to more than 45,000 controls, the hazard ratio for all thyroid cancers in GLP-1 users was 1.46. The hazard ratio for developing thyroid cancer with DPP-4 inhibitors was 1.1. GLP-1 receptors are present in normal and cancerous thyroid cells.
Endocrinology, Diabetes, Metabolism November 28th 2022